Work

Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective registry

Year: 2026
Type: article
Study design: Observational Study
Abstract: PURPOSE: Local failure and leptomeningeal disease (LMD) are both poor outcomes that can occur after resection and post-operative radiosurgery for newly diagnosed brain metastases (BM). There is increasing utilization of collagen-embedded Cesium-131 brachytherapy (GammaTile®) as a method of providing immediate adjuvant radiation therapy. Post-operative LMD rates following GammaTile implantation for newly diagnosed BMs has yet to be reported. The objective was to evaluate the incidence of LMD rates, local control (LC), and survival following resection and GammaTile for newly diagnosed BMs. METHODS: An ongoing, multicenter, prospective, observational Phase IV non-interventional registry (NCT0442738) was queried to analyze rates of LMD following surgical resection of newly diagnosed BMs. Following resection and GammaTile implantation, we evaluated LMD rates, LC, and overall survival (OS). The Kaplan-Meier method was used to analyze time-to-event outcomes. RESULTS: Fifty-one patients with 55 BMs were analyzed. The median follow-up was 12.4 months. The majority of BMs were in the supratentorial brain (87.3%). Four patients (7.8%) experienced LMD, 3 pachymeningeal and 1 classical. The 3-, 6-, and 12-month LMD-free rates were 97.4%, 94.1%, and 88.5%, respectively. The 12-month LC was 92.3%, and the 12-month OS was 49.0% with a median OS of 11.0 months. CONCLUSIONS: In this prospective registry study, GammaTile at the time of resection of newly diagnosed BMs was associated with high rates of tumor control and modest rates of LMD. As the trial registry continues to accrue, further data will continue to shed light on variables associated with outcomes.
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,590
Funders: Simons Foundation, James S. McDonnell Foundation, Jane Coffin Childs Memorial Fund for Medical Research, Pfizer, Takeda Science Foundation, Fundación Ramón Areces, University of Notre Dame, University of Maryland, Leukemia and Lymphoma Society of Canada, Qilu Hospital of Shandong University, Broad Institute, Apple, Paula and Rodger Riney Foundation, Mongolian Foundation for Science and Technology, University of Pretoria, Fondation Leducq, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Canada Research Chairs, National Natural Science Foundation of China, Ministero della Salute, Ligue Contre le Cancer, China Scholarship Council, Natural Science Foundation of Guangxi Province, Ministerio de Ciencia e Innovación, Institut National Du Cancer, Natural Science Foundation of Shandong Province, Peking University Third Hospital, Novo Nordisk Fonden, Higher Education Discipline Innovation Project, Universitas Padjadjaran, Thailand Science Research and Innovation, Natural Science Foundation for Young Scientists of Shanxi Province, National Institutes of Health, National Institute of Food and Agriculture, Canadian Institutes of Health Research, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, National Health and Medical Research Council, Japan Society for the Promotion of Science, Beijing Nova Program, Helse Sør-Øst RHF, National Key Research and Development Program of China, Netherlands Heart Institute, Conselleria de Cultura, Educación y Ciencia, Generalitat Valenciana, Shenzhen Science and Technology Innovation Program, Office of Naval Research, National Institute of Mental Health, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, SBE Office of Multidisciplinary Activities, National Center for Complementary and Integrative Health, HORIZON EUROPE European Innovation Council
OpenAlex ID: W7128213637
FWCI: 13.39
Cites:
Cited by: 3
Related to: